Galectin Therapeutics Inc. (GALT:NAQ) Soars 11.55% on Clinical Trial Success

On June 20, 2025, Galectin Therapeutics Inc. (GALT:NAQ) surged 11.55% in pre-market trading, marking a significant rise in its stock price.

Galectin Therapeutics Inc. has been making strides in the biotechnology sector, with its stock price reaching a new 52-week high during recent trading sessions. The company's innovative approach to developing therapies for liver diseases and cancer has garnered attention from investors, contributing to its recent stock price surge.

Galectin Therapeutics Inc. has been actively involved in clinical trials for its lead drug candidate, GR-MD-02, which is designed to treat non-alcoholic steatohepatitis (NASH). Positive results from these trials have bolstered investor confidence in the company's prospects, driving up its stock price.

In addition to its clinical progress, Galectin Therapeutics Inc. has also been expanding its partnerships and collaborations with other biotechnology companies. These strategic alliances have further enhanced the company's research and development capabilities, positioning it as a key player in the biotechnology industry.